Hims & Hers Health has agreed the $1.15bn acquisition of digital-health company, Eucalyptus, expanding the firm's presence in Australia and Japan, as well as UK, Germany and Canada.
Eucalyptus operates brands including Juniper and Pilot and has served more than 775,000 customers.
The company reports an annual revenue run-rate north of $450 million based on unaudited January 2026 billings and has published over 20 peer-reviewed articles, the company said.
“Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare,” said Andrew Dudum, founder and CEO of Hims & Hers.
Related reading
- Cristiano Ronaldo invests $7.5m in Herbalife's Pro2col software
- CrowdStrike adds its security platform to Microsoft Marketplace for Azure customers
- A week in biotech: Four IPOs launch in a single week as Eli Lilly breaks the trillion-dollar barrier
Following closing, Tim Doyle, current CEO of Eucalyptus, will become SVP of International at Hims & Hers. Approximately $240 million will be payable in cash at closing, with the remainder in guaranteed deferred payments over 18 months and earnouts tied to targets through early 2029.
The acquisition isexpected to close during the middle of calendar year 2026.
The recap
- Definitive agreement reached to acquire Eucalyptus, an international digital-health company.
- Transaction valued at up to $1.15 billion, subject to customary purchase price adjustments.
- Acquisition expected to close mid-2026, pending regulatory approvals and closing conditions.
